A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 2, 2014, Pages 117-121

  Cubillo, Antonio ^a,c   Hernando Requejo, Ovidio ^a,c   García García, Elena ^d   Rodriguez Pascual, Jesús ^a,c   De Vicente, Emilio ^a,c   Morelli, Pía ^b   Rubio, Carmen ^a,c   López Ríos, Fernando ^a,b   Muro, Avertano ^a,c   López, Ulpiano ^a,c   Prados, Susana ^a,c   Quijano, Yolanda ^a,c   Hidalgo, Manuel ^a,c,d  

^a Gynecolog ical and Genitourinary Tumors Programme Centro Integra Oncologico Clara Campal CIOCC   (Spain)

^b Therapeutics Targets Laboratory   (Spain)

^c UNIVERSIDAD SAN PABLO CEU   (Spain)

^d Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Molecular targets; Personalized treatment; Rectal cancer

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CD31 ANTIGEN; CETUXIMAB; DNA TOPOISOMERASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; CAMPTOTHECIN; DEOXYCYTIDINE; FLUOROURACIL; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN; TOP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MALE; MUTATIONAL ANALYSIS; PERSONALIZED MEDICINE; RECTUM CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT THERAPY; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; PILOT STUDY; PROCEDURES; PROSPECTIVE STUDY; RECTAL NEOPLASMS;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DNA TOPOISOMERASES, TYPE I; FEMALE; FLUOROURACIL; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; PHOSPHATIDYLINOSITOL 3-KINASES; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RADIOTHERAPY, INTENSITY-MODULATED; RAS PROTEINS; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84900473337     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31826e0703     Document Type: Article

References (35)

1. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005; 23:4553-4560.
2. Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 2009;27:1130-1136.
3. Sartore-Bianchi A, Martini M, Molinari F, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 2009;69:1851-1857.
4. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-762.
5. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254-1261.
6. Braun MS, Richman SD, Quirke P, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008;26:2690-2698.
7. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res. 2005;11:6100-6102.
8. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol. 2001;19:4298-4304.
9. Cascinu S, Aschele C, Barni S, et al. Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res. 1999;5:1996-1999.
10. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93:583-596.
11. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
12. Chan AK, Wong A, Jenken D, et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:665-677.
13. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355:1114-1123.
14. Rödel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25:110-117.
15. Gérard J-P, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase II trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638-1644.
16. Aschele CP, Cordio S, Rosati G, et al. Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial. J Clin Oncol. 2009;27(suppl):170s. abstr CRA4008.
17. Horisberger K, Treschl A, Mai S, et al. Cetuximab in combination with capecitabine irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys. 2009;74:1487-1493.
18. Koeberle D, Burkhard R, von Moos R, et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer. 2008;98:1204-1209.
19. Debuquov A, Haustermans K, Daemen A, et al. Molecularresponse to cetuximab and efficacy of preoperative cetuximabbased chemoradiation in rectal cancer. JCO. 2009;27:2751-2757.
20. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020-3026.
21. Rodriguez-Pascual J, García E, López-Ríos F, et al. Use of combined biomarkers analysis to predict response to chemotherapy in colorectal cancer: a single-institution feasibility study. J Clin Oncol. 2009;27(suppl):15s. abstr 11074.
22. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991.
23. Angulo B, García-García E, Martínez R, et al. A commercial realtime PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn. 2010;12:292-299.
24. Wahl R, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):1225-1505.
25. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-8696.
26. Duff SE, Jeziorska M, Kumar S, et al. Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis. 2007;9:793-800.
27. Strimpakos AS, Syrigos KN, Saif MW, et al. Pharmacogenetics and biomarkers in colorectal cancer. Pharmacogenomics J. 2009;9:147-160.
28. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008;26:5705-5712.
29. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67:2643-2648.
30. Purim O, Goldberg N, Kundel Y. Early prediction of pathological complete response (pCR) of rectal cancer after 1 week of preoperative radiochemotherapy (RCT) using positron emission computerized tomography (PET-CT) imaging. J Clin Oncol. 2011;suppl 4):29. abstr 572.
31. Cacheux W, Boisserie T, Staudacher L, et al. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol. 2008;19:1659-1661.
32. Bagri A, Berry L, Gunter B, et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res. 2010;16:3887-3900.
33. Mancuso MR, Davis R, Norberg SM, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116:2610-2621.
34. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004;10:145-147.
35. Dings R, Loren M, Heun H, et al. Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007;13: 3395-3398.